Demographic and socioeconomic patterns of malignant melanoma in junctional nevus: An NCDB analysis.
Abstract
e21572 Background: Malignant melanoma in junctional nevus (MMJN) is a rare type of cutaneous melanoma that originates in melanocytes located at the dermoepidermal junction. Although uncommon, malignant transformation in a junctional nevus is aggressive, with documented cases progressing to parotid and cervical lymph nodes as well as distant sites. Nevus-associated melanomas, including those arising in junctional nevi, have shown better overall prognosis independent of sentinel lymph node status. Due to MMJN being grouped with broader melanoma categories, we conducted a large-scale analysis of the NCDB to clarify demographic and socioeconomic factors influencing diagnosis and outcomes. Methods: A retrospective cohort analysis using NCDB data (2004–2020) was performed to evaluate demographic and socioeconomic characteristics of patients with MMJN (ICD-O-3 code 8740/3). Variables included age, sex, race, Hispanic origin, income, insurance, facility type, region, tumor features, surgical procedures, primary site, treatment, and Charlson-Deyo comorbidity score. Incidence trends were analyzed using descriptive statistics. Results: A total of 612 patients were identified with a stable incident trend over the study period (R²=0.18). Most were male (56.7%), White (97.5%), and non-Hispanic (93.0%), and had a mean age at diagnosis of 56.14 years (SD=16.83). The largest proportion were treated at academic/research programs (43.7%), in the Pacific region (35.0%), and lived in metro areas ≥250k population (78.8%). Private insurance (66.3%) and Medicare (27.1%) were most common. Nearly half lived in the highest income quartile (49.2%), and the mean travel distance was 32.4 miles. The trunk (37.8%) and lower limb/shoulder (25.4%) were the most frequent anatomical sites. Most tumors were Stage 0 (23.5%) or Stage I (28.4%); Stage II–IV disease were rare. The mean tumor size was 18.37 mm. Most patients had a Charlson–Deyo score of 0 (91.2%). Survival beyond thirty days (98.8%) and ninety days (98.5%) was high. Wide local excision (26.3%) and wide excision with sentinel node biopsy (24.5%) were the most common procedures. Few received radiation (1.5%), chemotherapy (0.5%), or immunotherapy (0.8%). Survival rates were 96.5% at two years, 92.0% at five years, and 78.1% at ten years. Conclusions: To our knowledge, this is the first NCDB analysis focused on MMJN, addressing a major gap in the literature on this rare neoplasm. Consistent with prior case studies describing nevus-associated melanoma, most patients were non-Hispanic, White, and presented with early-stage disease. This study also provides the first large-scale evaluation of socioeconomic characteristics, showing that most lived in higher-income metro regions and received care at academic centers. Further research is needed to determine how these demographic and socioeconomic patterns impact detection, treatment decisions, and long-term survival.
Article Details
Journal Info
Journal of Clinical Oncology
Lippincott Williams & Wilkins
Authors (7)
Elizabeth Hammer
University of California, Davis, Davis, CA
Eugene Manu
School of Natural Sciences and Mathematics, Hofstra University, Hempstead, NY
Amber Chang
University of South Florida, Morsani College of Medicine, Tampa, FL
Suraj Puvvadi
Arizona State University, Tempe, AZ
Akaash Surendra
Arizona State University, Tempe, AZ
Beau Hsia
Creighton University School of Medicine-Phoenix, Phoenix, AZ
Craig Heise
University of Arizona College of Medicine, Phoenix, AZ